Switch to:
Also traded in: Denmark, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 18009.02
GNMSF's Cash to Debt is ranked higher than
100% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GNMSF: 18009.02 )
Ranked among companies with meaningful Cash to Debt only.
GNMSF' s Cash to Debt Range Over the Past 10 Years
Min: 10.54  Med: 2677.54 Max: 18009.02
Current: 18009.02
10.54
18009.02
Equity to Asset 0.87
GNMSF's Equity to Asset is ranked higher than
77% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GNMSF: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
GNMSF' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.45 Max: 0.87
Current: 0.87
0.21
0.87
Interest Coverage No Debt
GNMSF's Interest Coverage is ranked higher than
75% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNMSF: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GNMSF' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 65.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 63.58
GNMSF's Operating margin (%) is ranked higher than
97% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. GNMSF: 63.58 )
Ranked among companies with meaningful Operating margin (%) only.
GNMSF' s Operating margin (%) Range Over the Past 10 Years
Min: -434.42  Med: -76.81 Max: 31.18
Current: 63.58
-434.42
31.18
Net-margin (%) 66.99
GNMSF's Net-margin (%) is ranked higher than
97% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. GNMSF: 66.99 )
Ranked among companies with meaningful Net-margin (%) only.
GNMSF' s Net-margin (%) Range Over the Past 10 Years
Min: -399.56  Med: -119.96 Max: 35.43
Current: 66.99
-399.56
35.43
ROE (%) 15.13
GNMSF's ROE (%) is ranked higher than
88% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GNMSF: 15.13 )
Ranked among companies with meaningful ROE (%) only.
GNMSF' s ROE (%) Range Over the Past 10 Years
Min: -112.03  Med: -33.19 Max: 22.38
Current: 15.13
-112.03
22.38
ROA (%) 11.94
GNMSF's ROA (%) is ranked higher than
91% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GNMSF: 11.94 )
Ranked among companies with meaningful ROA (%) only.
GNMSF' s ROA (%) Range Over the Past 10 Years
Min: -36.89  Med: -27.17 Max: 13.1
Current: 11.94
-36.89
13.1
ROC (Joel Greenblatt) (%) 1420.04
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GNMSF: 1420.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMSF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -675.71  Med: -36.60 Max: 1097
Current: 1420.04
-675.71
1097
Revenue Growth (3Y)(%) 23.90
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
81% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GNMSF: 23.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMSF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.85 Max: 331.5
Current: 23.9
0
331.5
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 68.45
GNMSF's P/E(ttm) is ranked lower than
79% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 26.73 vs. GNMSF: 68.45 )
Ranked among companies with meaningful P/E(ttm) only.
GNMSF' s P/E(ttm) Range Over the Past 10 Years
Min: 42.72  Med: 85.10 Max: 125.14
Current: 68.45
42.72
125.14
PE(NRI) 68.45
GNMSF's PE(NRI) is ranked lower than
74% of the 271 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. GNMSF: 68.45 )
Ranked among companies with meaningful PE(NRI) only.
GNMSF' s PE(NRI) Range Over the Past 10 Years
Min: 42.64  Med: 85.06 Max: 181.04
Current: 68.45
42.64
181.04
P/B 9.88
GNMSF's P/B is ranked lower than
99.99% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. GNMSF: 9.88 )
Ranked among companies with meaningful P/B only.
GNMSF' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 7.22 Max: 25.05
Current: 9.88
1.63
25.05
P/S 49.43
GNMSF's P/S is ranked lower than
86% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. GNMSF: 49.43 )
Ranked among companies with meaningful P/S only.
GNMSF' s P/S Range Over the Past 10 Years
Min: 4  Med: 15.77 Max: 96.56
Current: 49.43
4
96.56
POCF 440.20
GNMSF's POCF is ranked lower than
96% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. GNMSF: 440.20 )
Ranked among companies with meaningful POCF only.
GNMSF' s POCF Range Over the Past 10 Years
Min: 3.67  Med: 64.66 Max: 1667.07
Current: 440.2
3.67
1667.07
Current Ratio 7.12
GNMSF's Current Ratio is ranked higher than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GNMSF: 7.12 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.85 Max: 7.12
Current: 7.12
1.3
7.12
Quick Ratio 7.12
GNMSF's Quick Ratio is ranked higher than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GNMSF: 7.12 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.85 Max: 7.12
Current: 7.12
1.3
7.12

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -9.81
GNMSF's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. GNMSF: -9.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMSF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.81  Med: 1.00 Max: 309.9
Current: -9.81
-9.81
309.9

More Statistics

Revenue(Mil) $121
EPS $ 1.08
Beta0.98
Short Percentage of Float0.00%
52-Week Range $70.55 - 132.00
Shares Outstanding(Mil)59.32

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S is a biotechnology company that utilizes antibody products. The Company's treatments focus on cancer and other serious illnesses. The Company has a pipeline of drugs in various stages of development and approval. The Company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The Company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The Company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The Company has a myriad of other products in development, pending completion and approval. The Company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab A/S : Undervalued relative to peers, but don’t ignore the other factors Feb 10 2016
Major Shareholder Announcement Feb 04 2016
Genmab A/S – Value Analysis (US OTC:GNMSF) : January 29, 2016 Jan 29 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : January 29, 2016 Jan 29 2016
Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) as Extended Treatment for Recurrent or... Jan 19 2016
Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen Dec 21 2015
Genmab Achieves $3 Million Milestone for Progress in DuoBody Platform Collaboration with Janssen Dec 18 2015
Genmab Achieves USD 5 Million Milestone in Daratumumab Collaboration with Janssen Dec 09 2015
Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned... Nov 23 2015
Genmab Achieves USD 45 Million Milestone in DARZALEX(TM) (daratumumab) Collaboration With Janssen Nov 19 2015
Major Shareholder Announcement Nov 17 2015
Genmab Announces U.S. FDA Approval of DARZALEX(TM) (daratumumab) for Multiple Myeloma and Updates... Nov 16 2015
Genmab A/S breached its 50 day moving average in a Bearish Manner : October 16, 2015 Oct 16 2015
ETF’s with exposure to Genmab A/S : September 29, 2015 Sep 29 2015
Genmab A/S breached its 50 day moving average in a Bearish Manner : September 29, 2015 Sep 29 2015
Genmab A/S breached its 50 day moving average in a Bullish Manner : September 10, 2015 Sep 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK